Payments linked to higher odds of doctors prescribing certain cancer drugs

June 1, 2017 by Bill Schaller

Physicians paid by pharmaceutical companies for meals, talks and travel had higher odds of prescribing those companies' drugs to treat two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led study has found.

In preliminary findings (abstract 6510) that will be presented at the American Society of Clinical Oncology Annual Meeting 2017 in Chicago on Saturday, June 3, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received these "general" payments from. While they found that these payments for lodging and meals were linked to higher odds of prescribing certain drugs, that wasn't consistently the case for payments for research.

"Ideally, therapy choices should be based on two things, and two things only: medical evidence and patient preference," said Aaron Mitchell, MD, a fellow in the UNC School of Medicine Division of Hematology & Oncology and the study's lead author. "As patient advocates, we should try to eliminate any barriers to this. We saw a pretty consistent increase in prescribing of a company's stemming from what we call 'general payments,' which don't go directly for research, but instead are paid to physicians for consulting, meals, travel and lodging for conferences or talks. This raises the possibility that drug companies are able to influence prescribing practices through gifts to physicians."

Last year, several research groups identified links between pharmaceutical payments and prescription practices. A 2016 study published in JAMA Internal Medicine determined that doctors who received a single meal promoting a certain brand-name drug prescribed those drugs for depression, high cholesterol and heart disease at higher rates. Another study in the same journal last year found a link between industry payments and higher rates of prescriptions for brand-name cholesterol drugs. In oncology, the stakes are high, Mitchell said, since cancer drugs can have significant side effects and financial costs.

"This pattern is worrisome since promotional efforts by tend to focus on newer products, which may steer providers and patients to more expensive treatments," said the study's senior author Stacie B. Dusetzina, PhD, a UNC Lineberger member and assistant professor in the UNC Eshelman School of Pharmacy and Gillings School of Global Public Health. "This could ultimately drive up costs for patients and taxpayers."

To examine whether company payments are influencing prescription choice in cancer care, researchers analyzed prescription patterns for Medicare patients with two cancers where there are multiple treatment options - metastatic renal cell cancer, which is a type of kidney cancer, and chronic myeloid leukemia, a blood cancer. They used publicly available data reported through Open Payments, a provision of the federal Patient Protection and Affordable Care Act that required U.S. drug and device manufacturers to disclose transfers of financial value greater than $10 to physicians and teaching hospitals.

"We chose these specific drugs because they are felt to be equally efficacious based on clinical trials," Mitchell said. "However, they do have differences in side effect profiles that a patient taking one of these drugs would notice and feel."

Compared to physicians who didn't receive any payments, those who received general payments for meals and lodging from a drug manufacturer had higher odds of prescribing that company's particular drug for both metastatic renal cell carcinoma, and for chromic myeloid leukemia. For renal cell carcinoma, odds were 78 percent higher, and for chronic myeloid leukemia, odds were 29 percent higher.

The average amount that physicians received in general payments was $566 for , and $166 for .

"Even for physicians who received very small payments, we still saw a change in prescription rates," Mitchell said. "It looks like this shakes out to be a really good buy for a drug company."

Meanwhile, they did not find a consistent relationship for physicians who received payments from pharmaceutical companies solely for research. This doesn't rule out the possibility of an association, however, Mitchell said.

He called for more research to explore the impact of research payments on prescription practices, and to uncover whether the association they found between general payments and prescription choice was a cause-and-effect relationship.

"This is a 'proof of principle' study, showing that there is an association between industry payments and prescribing in care, and that this may also be present for other treatment choices where the options are not equivalent," Mitchell said. "If evidence emerges to show that drug industry payments are not only associated with changes in practice, but cause these changes, then we need to find some solution to prevent physician-industry relationships from influencing physicians in such a manner," he added.

Explore further: Doctors should question the value of most heavily promoted drugs

Related Stories

Doctors should question the value of most heavily promoted drugs

May 2, 2017
Top promoted drugs are less likely than top selling and top prescribed drugs to be effective, safe, affordable, novel, and represent a genuine advance in treating a disease, argue US researchers in The BMJ today.

Study finds links between physicians setting cancer care guidelines and drug industry

August 25, 2016
Nearly nine out of 10 physicians and researchers who helped develop a leading set of cancer care guidelines in the United States reported financial ties to the pharmaceutical and medical device industries, a University of ...

Types and distribution of payments from industry to physicians

May 2, 2017
In 2015, nearly half of physicians were reported to have received a total of $2.4 billion in industry-related payments, primarily involving general payments (including consulting fees and food and beverage), with a higher ...

Pharmaceutical industry-sponsored meals associated with higher prescribing rates

June 20, 2016
Accepting a single pharmaceutical industry-sponsored meal was associated with higher rates of prescribing certain drugs to Medicare patients by physicians, with more, and costlier, meals associated with greater increases ...

What's the real extent of industry payments to doctors?

March 6, 2017
More than three in every five Americans see a doctor who receives some form of payment from industry. This is according to a new survey led by Genevieve Pham-Kanter of Drexel University's Dornsife School of Public Health ...

Doctors paid by drug companies more likely to use those companies' meds

August 18, 2016
Ophthalmologists who receive money from pharmaceutical companies are more likely to prescribe medications promoted by those companies than similar drugs that are less costly, a new study shows.

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.